Turmeric and Cholesterol

Table of Contents

1. LDL, HDL and Triglycerides, Explained
2. A Lipid Number Is a Marker, Not an Outcome
3. The 2014 Meta-Analysis That Found Nothing
4. The 2019 Curcuminoid Analysis
5. The 2017 Analysis in People at Cardiovascular Risk
6. Curcumin Plus Piperine and the Lipid Profile
7. Why Four Meta-Analyses Disagree
8. Triglycerides: Where the Signal Is Least Unreliable
9. What This Is Not: A Statin Substitute
10. What to Do With This
11. Cautions
12. Key Research Papers
13. Connections
14. Featured Videos

LDL, HDL and Triglycerides, Explained

Fat does not dissolve in water, and blood is mostly water. To move fat around your body, your liver packages it inside protein-coated spheres called lipoproteins. Picture submarines: an oily cargo inside, a water-friendly shell outside. The names on your lab report are the different classes of submarine.

LDL — low-density lipoprotein. These carry cholesterol from the liver out to the tissues that need it, and every cell in your body does need cholesterol; it is a structural component of cell membranes and the raw material for vitamin D, bile acids and every steroid hormone you make. Cholesterol is not a poison. The problem is quantity and traffic. When there are a great many LDL particles in circulation, some of them lodge in the wall of an artery, become oxidised, and set off an inflammatory response that builds the plaque of atherosclerosis. This is why LDL is called the "bad" cholesterol, which is a misleading nickname for a necessary delivery vehicle in excessive traffic.

One refinement worth knowing: the number of LDL particles predicts risk better than the amount of cholesterol they collectively carry. Two people with the same LDL cholesterol can have very different particle counts. Almost none of the turmeric trials measured particle number; they measured LDL cholesterol, the cruder figure.

HDL — high-density lipoprotein. These run the other way, collecting excess cholesterol from tissues and artery walls and returning it to the liver — reverse cholesterol transport. Higher HDL tracks with lower cardiovascular risk in population studies, which earned it the "good" label. But the story turned out to be more complicated: drugs that raised HDL substantially failed to reduce cardiovascular events in large trials. HDL appears to be a marker of something healthy rather than the healthy thing itself. Treat any claim that a supplement "raises good cholesterol" with that history in mind.

Triglycerides. Not cholesterol at all — these are the fat molecules your body uses for fuel and storage, three fatty acid chains attached to a glycerol backbone. They rise after meals, particularly meals heavy in refined carbohydrate and alcohol, and they run high in insulin resistance, fatty liver and metabolic syndrome. Triglycerides are the most changeable of the three, moving substantially within weeks of a dietary change.

Total cholesterol is roughly the sum of everything, and is the least useful number on the panel. A high total driven by high HDL means something different from a high total driven by high LDL.

Back to Table of Contents

A Lipid Number Is a Marker, Not an Outcome

This deserves its own section because the entire page depends on it.

Nobody has ever died of a number on a lipid panel. The reason cholesterol matters is that across enormous populations, higher LDL predicts more heart attacks and strokes. That relationship is strong, consistent and supported by genetic evidence: people born with variants that give them lifelong low LDL have markedly less heart disease. LDL is about as good as a surrogate endpoint gets.

Even so, moving a marker is not the same as preventing an event, and the distinction has bitten cardiology repeatedly. Drugs that raised HDL did not deliver the benefit their marker predicted. Some drugs that lowered LDL by mechanisms other than the statin pathway have produced less benefit than the LDL drop implied. The reliability of a surrogate is specific to the intervention, not just to the marker — lowering LDL with a statin has been shown to prevent events; lowering it with something else has to be demonstrated separately, not assumed.

So when a meta-analysis reports that curcumin reduced LDL by some number of milligrams per decilitre, the correct reading is: a number associated with risk moved a little, in small short trials. No turmeric trial has ever counted heart attacks, strokes or deaths in a population where lipids were the target. The step from "the marker improved" to "fewer people had heart attacks" has not been taken, and it is not a small step.

Back to Table of Contents

The 2014 Meta-Analysis That Found Nothing

The first serious attempt to pool this literature appeared in Clinical Nutrition in 2014, gathering the randomised controlled trials then available on curcumin and blood lipid levels. Its conclusion was that curcumin supplementation did not produce a statistically significant change in the lipid fractions examined.

That is an unglamorous result and it is the single most useful data point on this page — not because a null result proves absence of effect, but because it establishes the starting position. In 2014, with the trials that existed then, there was no detectable lipid effect to find. Everything positive reported since has been built on trials published afterwards, or on pooling strategies that include studies the earlier analysis did not.

Two honest caveats cut in opposite directions. In favour of the null: it was an unbiased look at the evidence as it stood, published by an author who has since produced a great deal of positive curcumin research, which makes the negative finding harder to dismiss as hostile. Against the null: the pool was small, and small pools have low statistical power — a genuine modest effect could easily hide inside confidence intervals that wide. "We did not detect an effect" is not the same statement as "there is no effect."

What it does establish is that anyone claiming turmeric is a reliable cholesterol-lowering agent has to explain why the first proper look at the evidence found nothing.

Back to Table of Contents

The 2019 Curcuminoid Analysis

A 2019 systematic review and meta-analysis in Critical Reviews in Food Science and Nutrition examined the lipid-modifying activity of curcuminoids across the randomised controlled trial literature, with a larger pool of studies than was available five years earlier.

Its framing is worth noting. The analysis is about curcuminoids — the family of three related yellow pigments in turmeric root, of which curcumin is the most abundant, alongside demethoxycurcumin and bisdemethoxycurcumin. Commercial extracts are standardised to total curcuminoid content, typically around 95 percent, so most trials are in truth testing the mixture rather than pure curcumin. The three compounds differ in stability and in absorption, which is one more reason products behave differently from one another.

The analysis reported lipid-modifying activity for curcuminoids, with the clearest and most consistent movement in triglycerides. Effects on LDL and HDL were smaller and less consistent across the included trials. That pattern — triglycerides responsive, LDL stubborn — recurs throughout this literature and is discussed below.

Back to Table of Contents

The 2017 Analysis in People at Cardiovascular Risk

A 2017 meta-analysis in Nutrition Journal asked a narrower and more clinically useful question: not whether turmeric changes lipids in anybody, but whether it does so in people who already carry cardiovascular risk factors. It pooled a substantial set of randomised trials in that population and reported reductions in blood lipid levels, with LDL cholesterol and triglycerides the fractions where the pooled effect was clearest.

Restricting the population this way is methodologically sound. Lipid-lowering interventions generally do more in people whose lipids are abnormal to begin with — there is more room to move, and regression toward the mean helps rather than hides. A trial in healthy young volunteers with normal panels will find little regardless of whether the intervention works, simply because there is nothing to fix.

The usual caveats apply and should not be skipped. The included trials were mostly small and short. The turmeric preparations varied widely in form, dose and absorption. Statistical heterogeneity in analyses of this literature tends to be high, which means the included trials were not all measuring the same thing, and the pooled average therefore describes no particular trial well. And a pooled effect of a few milligrams per decilitre on LDL — the order of magnitude at stake here — is not a number that changes clinical decisions.

Back to Table of Contents

Curcumin Plus Piperine and the Lipid Profile

Because plain curcumin is so poorly absorbed, a large share of commercial products bundle it with piperine from black pepper, which slows the liver and gut enzymes that would otherwise clear curcumin almost immediately. The 1998 Shoba study established the effect in humans and it has shaped the supplement market ever since.

A 2023 meta-analysis in Phytotherapy Research pooled the randomised trials that specifically used the curcumin-plus-piperine combination and looked at its effect on the lipid profile. Separating the combination products from plain extract is the right methodological move: they deliver very different amounts of curcumin to the bloodstream from the same milligram figure on the label, and treating them as one intervention is part of why this literature is so noisy.

There is a trade-off here that products rarely mention. Better absorption means more of the compound reaching tissue, which is what you want if it works — and also more of whatever risk accompanies it. Piperine simultaneously raises blood levels of a range of prescription medicines that share those metabolic pathways. And absorption-enhanced turmeric products have been over-represented in the published cases of turmeric-associated liver injury. A more effective delivery system is not automatically a safer one.

Back to Table of Contents

Why Four Meta-Analyses Disagree

A reader encountering four pooled analyses with four different conclusions is entitled to ask what is going on. Several things are, and they are worth understanding because they apply far beyond turmeric.

1. They pool different studies. Each analysis sets its own inclusion criteria — which populations, which minimum duration, which preparations, which languages, which years. Change the criteria and you change the answer. Two analyses of "the same" question can share only a minority of their included trials.
2. The interventions are not comparable. Plain curcuminoid extract, piperine-enhanced curcumin, phospholipid complexes, colloidal particles, whole turmeric powder: these deliver wildly different exposures. Averaging across them produces a number describing an intervention nobody actually takes.
3. The trials are small. Individual studies of 40 to 120 people have wide confidence intervals. Small studies also produce more extreme results in both directions, and the extreme positive ones are more likely to be published.
4. Publication bias. A small trial finding a benefit gets written up and accepted. A small trial finding nothing often does not. Over years this quietly tilts the pool, and the statistical tests for detecting it work poorly when the number of studies is modest.
5. Baseline lipids differ. A trial in people with markedly abnormal lipids will show a bigger drop than one in people close to normal, for reasons that have nothing to do with the supplement.
6. Duration differs. Lipid changes take weeks to stabilise. Four-week trials and six-month trials are not measuring the same thing.
7. Author overlap. A relatively small group of researchers produces a large share of both the primary trials and the meta-analyses in this field. That is normal in a specialised area and it is not misconduct, but it does mean these analyses are less independent of one another than four separate citations suggest.

The correct conclusion from four disagreeing meta-analyses is not to pick the one you like. It is that the underlying evidence is too weak and too heterogeneous to settle the question — which is itself a useful, honest answer.

Back to Table of Contents

Triglycerides: Where the Signal Is Least Unreliable

If there is a real lipid effect anywhere in this literature, triglycerides are the most likely place, and the reasons are biologically sensible rather than statistical.

Triglycerides are the lipid fraction most tightly coupled to insulin resistance and liver fat. When the liver is overloaded with fat and insulin signalling is impaired, it exports triglyceride-rich particles into the blood; improve insulin sensitivity or reduce liver fat and triglycerides tend to follow. Since the more plausible turmeric effects elsewhere in this leg — on insulin resistance, on liver fat on ultrasound, on inflammatory signalling — run through exactly that machinery, a triglyceride effect is the one that fits the rest of the picture instead of standing alone.

Triglycerides are also simply more movable than LDL. They respond within weeks to changes in refined carbohydrate, alcohol and weight, whereas LDL is anchored by hepatic receptor biology that is much harder to shift without a drug that targets it directly. An intervention with a modest metabolic effect will show up in triglycerides first, and may never show up in LDL at all.

Keep the same proportion here as everywhere else. Cutting alcohol, cutting refined carbohydrate and losing visceral fat move triglycerides far more than any capsule in this literature. The turmeric effect, if real, sits somewhere at the edge of what is worth measuring.

Back to Table of Contents

What This Is Not: A Statin Substitute

Statins are among the most thoroughly tested drugs in existence. They have been studied in hundreds of thousands of participants across dozens of large multi-centre trials, and their benefit is measured in the endpoint that matters: fewer heart attacks, fewer strokes, fewer deaths, in populations followed for years. The evidence is not about the LDL number. It is about what happened to the people.

Nothing in the turmeric literature is remotely comparable. There is no outcome trial. There is no trial powered for events of any kind. There is no multi-centre replication. There is a collection of small studies measuring blood chemistry over weeks to months, pooled by analyses that contradict each other.

You will encounter the claim that a trial showed curcumin performing as well as atorvastatin. A 2008 trial in people with type 2 diabetes did compare a standardised curcumin preparation with atorvastatin and with placebo — and it measured endothelial function, oxidative stress markers and inflammatory markers. It did not measure heart attacks, strokes or deaths, and it was small. Curcumin moving a laboratory marker in the same direction as a statin over eight weeks says nothing about whether it would prevent the events the statin is proven to prevent. That trial is discussed properly on the blood vessels and blood pressure page, where it belongs.

If a clinician has recommended a statin, that recommendation rests on your calculated cardiovascular risk and on outcome evidence. Turmeric does not substitute for it. If you have concerns about statins — muscle symptoms are the common one, and they are real — that is a conversation to have with the person who prescribed it, where dose changes and alternative agents exist. Swapping a proven drug for an unproven supplement is not a solution to a side effect.

Back to Table of Contents

What to Do With This

A short, practical position given everything above.

• Do not take turmeric for your cholesterol. The evidence does not support it as a lipid-lowering intervention, and expecting a meaningful LDL change is setting up for disappointment.
• Do not stop a prescribed lipid medication on the strength of anything on this page.
• If you take it for other reasons, that is fine. Joint symptoms, digestive comfort, or simply eating well-spiced food are all reasonable reasons to have turmeric in your life, and any lipid effect is then a bonus rather than the plan.
• Get the panel done properly. If lipids are a concern, get a full panel including triglycerides, and ask whether an ApoB or LDL particle number is appropriate — that measure predicts risk better than LDL cholesterol alone.
• Spend your effort where the evidence is. Dietary pattern, alcohol, refined carbohydrate, visceral fat, physical activity and sleep move lipids far more than any supplement in this literature, and they have outcome evidence behind them.
• If you measure, measure properly. Panel before starting, panel again at twelve weeks, same laboratory, same fasting conditions. Comparing a fasted result to a non-fasted one produces a triglyceride difference that has nothing to do with what you took.

Back to Table of Contents

Cautions

• Liver injury. Documented, uncommon and occasionally severe. A 2023 case series from the US Drug-Induced Liver Injury Network reported ten cases associated with turmeric supplements, with absorption-enhanced products prominent among them. Stop and seek medical attention for jaundice, dark urine, pale stools or persistent right-upper-abdominal pain.
• Blood thinners. Curcumin has antiplatelet activity in the laboratory. Discuss it with a prescriber if you take warfarin, a direct oral anticoagulant, clopidogrel or daily aspirin.
• Piperine interactions. The absorption enhancer raises levels of other drugs metabolised by the same enzymes, not only curcumin.
• Gallbladder disease. Turmeric stimulates gallbladder contraction and should be avoided in concentrated doses with gallstones or biliary obstruction.
• Iron. Curcumin chelates iron; high supplemental doses may worsen existing iron deficiency.
• Surgery. Stop one to two weeks before any planned procedure and tell the surgical team.

The full discussion is on the Turmeric Safety and Interactions leg.

Back to Table of Contents

Key Research Papers

1. Sahebkar A. (2014). A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clinical Nutrition. (The early pooled analysis that found no significant lipid effect.) — PubMed PMID: 24139527
2. Simental-Mendía LE, Pirro M, Gotto AM Jr, et al. (2019). Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Food Science and Nutrition. — PubMed PMID: 29185808
3. Qin S, Huang L, Gong J, et al. (2017). Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutrition Journal. — PubMed PMID: 29020971
4. Hosseini H, Ghavidel F, Panahi G, et al. (2023). A systematic review and meta-analysis of randomized controlled trials investigating the effect of the curcumin and piperine combination on lipid profile. Phytotherapy Research. — PubMed PMID: 36649934
5. Chuengsamarn S, Rattanamongkolgul S, Phonrat B, et al. (2014). Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. Journal of Nutritional Biochemistry. — PubMed PMID: 24445038
6. Yaikwawong M, Jansarikit L, Jirawatnotai S, et al. (2024). The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial. Nutrients. — PubMed PMID: 39125322
7. Usharani P, Mateen AA, Naidu MU, et al. (2008). Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus. Drugs in R&D. (Surrogate markers only; not an outcome comparison with a statin.) — PubMed PMID: 18588355
8. Shoba G, Joy D, Joseph T, et al. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. — PubMed PMID: 9619120
9. Nelson KM, Dahlin JL, Bisson J, et al. (2017). The Essential Medicinal Chemistry of Curcumin. Journal of Medicinal Chemistry. — PubMed PMID: 28074653
10. Gupta SC, Patchva S, Aggarwal BB. (2013). Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS Journal. — PubMed PMID: 23143785
11. Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. (2023). Liver Injury Associated with Turmeric — A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. American Journal of Medicine. — PubMed PMID: 36252717

PubMed Topic Searches

1. PubMed: Curcumin and LDL cholesterol, randomized trials
2. PubMed: Curcumin and triglycerides
3. PubMed: Turmeric and the lipid profile
4. PubMed: Curcumin and apolipoprotein B
5. PubMed: LDL particle number versus LDL cholesterol as a risk marker
6. PubMed: HDL-raising therapy and cardiovascular outcomes
7. PubMed: Publication bias in dietary supplement meta-analyses
8. PubMed: Statins and cardiovascular outcomes

Back to Table of Contents

Connections

• Turmeric for Heart and Metabolic Health
• Turmeric for Blood Sugar and Type 2 Diabetes
• Turmeric, Blood Vessels and Blood Pressure
• Turmeric for Fatty Liver and Metabolic Syndrome
• Turmeric
• Turmeric Bioavailability and Forms
• Turmeric Benefits
• Turmeric Safety and Interactions
• Turmeric for Digestive Health
• Javanese Turmeric
• Black Turmeric
• Culinary and Spice Herbs
• Gut Health
• All Herbs

Back to Table of Contents